CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 300 enrolled
Drug / intervention
BTA798 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01175226
NCT01175226Phase 2Completed
CompareCT.gov

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Biota Scientific Management Pty Ltd·interventional·Posted Aug 4, 2010·Updated May 31, 2018

In Brief

A Phase 2 clinical trial evaluating BTA798 and Placebo for Rhinovirus. Completed, enrolled 300 participants across 43 sites.

Detailed Summary

This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on * shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), * controlling asthma symptoms, and * lowering the risk of asthma symptoms worsening in subjects with asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinovirus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 4, 2010
Enrollment StartAug 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.9 years ago

Interventions

BTA798drug

BTA798 twice daily

Placebodrug

Placebo twice daily